Analysis of the Complete Open Reading Frame of Genotype 2b Hepatitis C Virus in Association with the Response to Peginterferon and Ribavirin Therapy

被引:6
|
作者
Kadokura, Makoto [1 ]
Maekawa, Shinya [1 ]
Sueki, Ryota [1 ]
Miura, Mika [1 ]
Komase, Kazuki [1 ]
Shindo, Hiroko [1 ]
Amemiya, Fumitake [1 ]
Uetake, Tomoyoshi [1 ]
Inoue, Taisuke [1 ]
Sakamoto, Minoru [1 ]
Nakagawa, Mina [2 ]
Sakamoto, Naoya [2 ]
Watanabe, Mamoru [2 ]
Enomoto, Nobuyuki [1 ]
机构
[1] Univ Yamanashi, Fac Med, Dept Internal Med 1, Chuo Ku, Yamanashi, Japan
[2] Tokyo Med & Dent Univ, Dept Gastroenterol & Hepatol, Bunkyo Ku, Tokyo, Japan
来源
PLOS ONE | 2011年 / 6卷 / 09期
关键词
PEGYLATED-INTERFERON-ALPHA; ACID SUBSTITUTION PATTERN; PROTEIN 5A GENE; HIGH VIRAL LOAD; COMBINATION THERAPY; VIROLOGICAL RESPONSE; AMERICAN PATIENTS; PLUS RIBAVIRIN; CORE PROTEIN; MUTATIONS;
D O I
10.1371/journal.pone.0024514
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background and Aims: Patients infected with genotype 2b hepatitis C virus (HCV) generally can achieve favorable responses to pegylated-interferon plus ribavirin therapy (PEG-IFN/RBV). However, a proportion of patients show poorer responses and the correlation between viral sequence variation and treatment outcome remains unclear. Methods: The pretreatment complete open reading frame (ORF) sequences of genotype 2b HCV determined by direct sequencing were investigated for correlation with the final outcome in a total of 60 patients. Results: In this study group, 87.5% (14/16) of non-sustained virological response (non-SVR) patients (n = 16) were relapsers. Compared to sustained virological response (SVR) patients (n = 44), non-SVR patients were older and could not achieve prompt viral clearance after the therapy induction. Comparing each viral protein between the two groups, viral sequences were more diverse in SVR patients and that diversity was found primarily in the E1, p7, and NS5A proteins. In searching for specific viral regions associated with the final outcome, several regions in E2, p7, NS2, NS5A, and NS5B were extracted. Among these regions, part of the interferon sensitivity determining region (ISDR) was included. In these regions, amino acid substitutions were associated with the final outcome in an incremental manner, depending upon the number of substitutions. Conclusions: Viral sequences are more diverse in SVR patients than non-SVR patients receiving PEG-IFN/RBV therapy for genotype-2b HCV infection. Through systematic comparison of viral sequences, several specific regions, including part of the ISDR, were extracted as having significant correlation with the final outcome.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Efficacy and Tolerability of Peginterferon α-2a and Peginterferon α-2b, Both plus Ribavirin, for Chronic Hepatitis C: A Meta-Analysis of Randomized Controlled Trials
    Yang, Zongguo
    Zhuang, Liping
    Yang, Lei
    Chen, Xiaorong
    GASTROENTEROLOGY RESEARCH AND PRACTICE, 2013, 2013
  • [32] Simeprevir (TMC435) once daily with peginterferon-α-2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO-4 study
    Kumada, Hiromitsu
    Hayashi, Norio
    Izumi, Namiki
    Okanoue, Takeshi
    Tsubouchi, Hirohito
    Yatsuhashi, Hiroshi
    Kato, Mai
    Rito, Ki
    Komada, Yuji
    Seto, Chiharu
    Goto, Shoichiro
    HEPATOLOGY RESEARCH, 2015, 45 (05) : 501 - 513
  • [33] Prediction of a Null Response to Pegylated Interferon α-2b Plus Ribavirin in Patients with High Viral Load Genotype 1b Hepatitis C
    Wada, Yuki
    Tamai, Hideyuki
    Kawashima, Akira
    Shingaki, Naoki
    Mori, Yoshiyuki
    Kawaguchi, Masanori
    Moribata, Kosaku
    Deguchi, Hisanobu
    Ueda, Kazuki
    Inoue, Izumi
    Maekita, Takao
    Iguchi, Mikitaka
    Kato, Jun
    Ichinose, Masao
    GUT AND LIVER, 2014, 8 (04) : 421 - 427
  • [34] Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1
    Kowdley, Kris V.
    Lawitz, Eric
    Poordad, Fred
    Cohen, Daniel E.
    Nelson, David R.
    Zeuzem, Stefan
    Everson, Gregory T.
    Kwo, Paul
    Foster, Graham R.
    Sulkowski, Mark S.
    Xie, Wangang
    Pilot-Matias, Tami
    Liossis, George
    Larsen, Lois
    Khatri, Amit
    Podsadecki, Thomas
    Bernstein, Barry
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (03) : 222 - 232
  • [35] Insulin Resistance Predicts Rapid Virologic Response to Peginterferon/Ribavirin Combination Therapy in Hepatitis C Genotype 4 Patients
    Khattab, Mahmoud
    Eslam, Mohammed
    Sharwae, Mohammed Ahmed
    Shatat, Mohammed
    Ali, Ahmed
    Hamdy, Lamia
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 (09) : 1970 - 1977
  • [36] Meloxicam as an adjuvant to peginterferon-α-2a and ribavirin treatment for genotype 1 chronic hepatitis C: A randomized trial
    Kagawa, Tatehiro
    Kojima, Sei-ichiro
    Shiraishi, Koichi
    Hirose, Shunji
    Arase, Yoshitaka
    Takashimizu, Shinji
    Watanabe, Norihito
    Nagata, Naruhiko
    Numata, Makoto
    Shiozawa, Hirokazu
    Nishizaki, Yasuhiro
    Toki, Mayu
    Sugita, Teruji
    Nomura, Kijuro
    Sakaguchi, Takashi
    Atsukawa, Kazuhiro
    Tajima, Hiroto
    Tei, Yoshihiro
    Inomoto, Tsutomu
    Mine, Tetsuya
    HEPATOLOGY RESEARCH, 2013, 43 (09) : 925 - 932
  • [37] A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C
    Hara, Tasuku
    Akuta, Norio
    Suzuki, Fumitaka
    Sezaki, Hitomi
    Suzuki, Yoshiyuki
    Hosaka, Tetsuya
    Kobayashi, Masahiro
    Kobayashi, Mariko
    Saitoh, Satoshi
    Kumada, Hiromitsu
    JOURNAL OF MEDICAL VIROLOGY, 2013, 85 (10) : 1746 - 1753
  • [38] Hepatitis C Virus Genotype 2/3 Patients Who Can Receive an Abbreviated Course of Peginterferon/Ribavirin: The Important Role of Initial Ribavirin Doses Reply
    Diago, Moises
    HEPATOLOGY, 2010, 51 (05) : 1862 - 1864
  • [39] Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin
    Huang, Chung-Feng
    Huang, Jee-Fu
    Yang, Jeng-Fu
    Hsieh, Ming-Yen
    Lin, Zu-Yau
    Chen, Shinn-Cherng
    Wang, Liang-Yen
    Juo, Suh-Hang Hank
    Chen, Ku-Chung
    Chuang, Wan-Long
    Kuo, Hsing-Tao
    Dai, Chia-Yen
    Yu, Ming-Lung
    JOURNAL OF HEPATOLOGY, 2012, 56 (01) : 34 - 40
  • [40] The pattern of pegylated interferon-α2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype
    Aghemo, Alessio
    Rumi, Maria Grazia
    Monico, Sara
    Prati, Gian Maria
    D'Ambrosio, Roberta
    Donato, Maria Francesca
    Colombo, Massimo
    ANTIVIRAL THERAPY, 2009, 14 (04) : 577 - 584